Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 6, 2016, Pages 1631-1638

  Nolte, Hendrik ^a   Bernstein, David I ^b   Nelson, Harold S ^c   Kleine Tebbe, Jörg ^d   Sussman, Gordon L ^e   Seitzberg, Dorthe ^f   Rehm, Dorte ^f   Kaur, Amarjot ^a   Li, Ziliang ^a   Lu, Susan ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

^d Allergie and Asthma Zentrum Westend   (Germany)

^e UNIVERSITY OF TORONTO   (Canada)

^f ALK ABELLÓ   (Denmark)

Author keywords

adolescents; Allergen immunotherapy; allergic rhinoconjunctivitis; house dust mite; North America; sublingual immunotherapy tablet

Indexed keywords

EPINEPHRINE; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; PLACEBO;

ADOLESCENT; ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ALLERGIC REACTION; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CHILD; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EAR PRURITUS; EDEMA; FEMALE; GLOSSODYNIA; HOUSE DUST ALLERGY; HUMAN; LIP DISEASE; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; NAUSEA; NORTH AMERICAN; ORAL PRURITUS; PALATAL SWELLING; PHARYNX DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS DAILY MEDICATION SCORE; RHINITIS DAILY SYMPTOM SCORE; RHINOCONJUNCTIVITIS; SUBLINGUAL IMMUNOTHERAPY; SWELLING; THROAT IRRITATION; TONGUE SWELLING; TONGUE ULCER; UPPER ABDOMINAL PAIN; VISUAL ANALOG SCALE; ANIMAL; CONJUNCTIVITIS, ALLERGIC; IMMUNOLOGY; MIDDLE AGED; PLACEBO EFFECT; PROCEDURES; PYROGLYPHIDAE; RHINITIS, ALLERGIC; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; CHILD; CONJUNCTIVITIS, ALLERGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; PYROGLYPHIDAE; RHINITIS, ALLERGIC; SUBLINGUAL IMMUNOTHERAPY; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84995461000     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.06.044     Document Type: Article

References (42)

1. 1 Matsuoka, T., Shamji, M.H., Durham, S.R., Allergen immunotherapy and tolerance. Allergol Int 62 (2013), 403–413.
2. 2 Durham, S.R., Emminger, W., Kapp, A., de Monchy, J.G., Rak, S., Scadding, G.K., et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 129 (2012), 717–725.e5.
3. 3 Corzo, J.L., Carrillo, T., Pedemonte, C., Plaza Martin, A.M., Martin Hurtado, S., Dige, E., et al. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol 24 (2014), 154–161.
4. 4 Maloney, J., Prenner, B.M., Bernstein, D.I., Lu, S., Gawchik, S., Berman, G., et al. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites. Ann Allergy Asthma Immunol 116 (2016), 59–65.
5. 5 Nolte, H., Maloney, J., Nelson, H.S., Bernstein, D.I., Lu, S., Li, Z., et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol 135 (2015), 1494–1501.e6.
6. 6 Demoly, P., Emminger, W., Rehm, D., Backer, V., Tommerup, L., Kleine-Tebbe, J., Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ-HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol 137 (2016), 444–451.
7. 7 Mosbech, H., Deckelmann, R., de Blay, F., Pastorello, E.A., Trebas-Pietras, E., Andres, L.P., et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 134 (2014), 568–575.e7.
8. 8 Virchow, J.C., Backer, V., Kuna, P., Prieto, L., Villesen, H.H., Ljorring, C., et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial. JAMA 315 (2016), 1715–1725.
9. 9 Arbes, S.J. Jr., Gergen, P.J., Elliott, L., Zeldin, D.C., Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 116 (2005), 377–383.
10. 10 Bush, R.K., Swenson, C., Fahlberg, B., Evans, M.D., Esch, R., Morris, M., et al. House dust mite sublingual immunotherapy: results of a US trial. J Allergy Clin Immunol 127 (2011), 974–981 e1-7.
11. 11 Henmar, H., Frisenette, S.M.T., Grosch, K., Nielsen, K., Smith, G., Sonderkaer, S., et al. Fractionation of source materials leads to high reproducibility of SQ-HDM SLIT-tablets. Int Arch Allergy Immunol 169 (2016), 23–32.
12. 12 Passalacqua, G., Baena-Cagnani, C.E., Bousquet, J., Canonica, G.W., Casale, T.B., Cox, L., et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 132 (2013), 93–98.
13. 13 Canonica, G.W., Baena-Cagnani, C.E., Bousquet, J., Bousquet, P.J., Lockey, R.F., Malling, H.J., et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 62 (2007), 317–324.
14. 14 Creticos, P.S., Maloney, J., Bernstein, D.I., Casale, T., Kaur, A., Fisher, R., et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol 131 (2013), 1342–1349.e6.
15. 15 Nelson, H.S., Nolte, H., Creticos, P., Maloney, J., Wu, J., Bernstein, D.I., Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 127 (2011), 72–80.e2.
16. 16 Nolte, H., Amar, N., Bernstein, D.I., Lanier, B.Q., Creticos, P., Berman, G., et al. Safety and tolerability of a short ragweed sublingual immunotherapy tablet. Ann Allergy Asthma Immunol 113 (2014), 93–100.e3.
17. 17 Allergenic Products Advisory Committee (APAC) meeting, December 12, 2013. US Food and Drug Administration: 2013.
18. 18 Wilson, A.M., O'Byrne, P.M., Parameswaran, K., Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 116 (2004), 338–344.
19. 19 Matricardi, P.M., Kuna, P., Panetta, V., Wahn, U., Narkus, A., Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J Allergy Clin Immunol 128 (2011), 791–799.e6.
20. 20 Devillier, P., Dreyfus, J.F., Demoly, P., Calderon, M.A., A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med, 12, 2014, 71.
21. 21 Durham, S.R., Creticos, P.S., Nelson, H.S., Li, Z., Kaur, A., Meltzer, E.O., et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: pooled analyses. J Allergy Clin Immunol 138 (2016), 1081–1088.e4.
22. 22 Scadding, G.K., Richards, D.H., Price, M.J., Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol Allied Sci 25 (2000), 551–557.
23. 23 Rodrigo, G.J., Neffen, H., Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review. Clin Exp Allergy 41 (2011), 160–170.
24. 24 Pfaar, O., Gerth van Wijk, R., Mite-allergic rhinitis: how to evaluate clinical efficacy in allergen-specific immunotherapy trials?. Curr Treat Options Allergy 2 (2015), 1–9.
25. 25 Cook, D.L., The Hawthorne effect in educational research. Phi Delta Kappan 44 (1962), 116–122.
26. 26 Nelson, H.S., Oral/sublingual Phleum pretense grass tablet (Grazax/Grastek) to treat allergic rhinitis in the USA. Expert Rev Clin Immunol 10 (2014), 1437–1451.
27. 27 Maloney, J., Bernstein, D.I., Nelson, H., Creticos, P., Hebert, J., Noonan, M., et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 112 (2014), 146–153.e2.
28. 28 Blaiss, M., Maloney, J., Nolte, H., Gawchik, S., Yao, R., Skoner, D.P., Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 127 (2011), 64–71.e4.
29. 29 Nolte, H., Hebert, J., Berman, G., Gawchik, S., White, M., Kaur, A., et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol 110 (2013), 450–456.e4.
30. 30 Calderon, M.A., Casale, T.B., Nelson, H.S., Demoly, P., An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol 132 (2013), 1322–1336.
31. 31 Nelson, H.S., Update on house dust mite immunotherapy: are more studies needed?. Curr Opin Allergy Clin Immunol 14 (2014), 542–548.
32. 32 Passalacqua, G., Pasquali, M., Ariano, R., Lombardi, C., Giardini, A., Baiardini, I., et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 61 (2006), 849–854.
33. 33 Tonnel, A.B., Scherpereel, A., Douay, B., Mellin, B., Leprince, D., Goldstein, N., et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 59 (2004), 491–497.
34. 34 Bozek, A., Ignasiak, B., Filipowska, B., Jarzab, J., House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis. Clin Exp Allergy 43 (2013), 242–248.
35. 35 Bergmann, K.C., Demoly, P., Worm, M., Fokkens, W.J., Carrillo, T., Tabar, A.I., et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 133 (2014), 1608–1614.e6.
36. 36 Wang, D.H., Chen, L., Cheng, L., Li, K.N., Yuan, H., Lu, J.H., et al. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope 123 (2013), 1334–1340.
37. 37 Pichler, C.E., Marquardsen, A., Sparholt, S., Lowenstein, H., Bircher, A., Bischof, M., et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 52 (1997), 274–283.
38. 38 Riechelmann, H., Schmutzhard, J., van der Werf, J.F., Distler, A., Kleinjans, H.A., Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis. Am J Rhinol Allergy 24 (2010), e104–e109.
39. 39 Yukselen, A., Kendirli, S.G., Yilmaz, M., Altintas, D.U., Karakoc, G.B., Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy. Asian Pac J Allergy Immunol 31 (2013), 233–241.
40. 40 Passalacqua, G., Albano, M., Fregonese, L., Riccio, A., Pronzato, C., Mela, G.S., et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 351 (1998), 629–632.
41. 41 Bufe, A., Eberle, P., Franke-Beckmann, E., Funck, J., Kimmig, M., Klimek, L., et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 123 (2009), 167–173.e7.
42. 42 Dahl, R., Kapp, A., Colombo, G., de Monchy, J.G., Rak, S., Emminger, W., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118 (2006), 434–440.